Portal de Periódicos da CAPES

The efficacy and safety of Iodine-131-metaiodobenzylguanidine therapy in patients with neuroblastoma: a meta-analysis

2022; BioMed Central; Volume: 22; Issue: 1 Linguagem: Inglês

10.1186/s12885-022-09329-2

1471-2407

Huihui He, Qiaoling Xu, Chunjing Yu,

Adrenal and Paraganglionic Tumors

Abstract Objective Neuroblastoma is a common extracranial solid tumor of childhood. Recently, multiple treatments have been practiced including Iodine-131-metaiodobenzylguanidine radiation ( 131 I-MIBG) therapy. However, the outcomes of efficacy and safety vary greatly among different studies. The aim of this meta-analysis is to evaluate the efficacy and safety of 131 I-MIBG in the treatment of neuroblastoma and to provide evidence and hints for clinical decision-making. Methods Medline, EMBASE database and the Cochrane Library were searched for relevant studies. Eligible studies utilizing 131 I-MIBG in the treatment of neuroblastoma were included. The pooled outcomes (response rates, adverse events rates, survival rates) were calculated using either a random-effects model or a fixed-effects model considering of the heterogeneity. Results A total of 26 clinical trials including 883 patients were analyzed. The pooled rates of objective response, stable disease, progressive disease, and minor response of 131 I-MIBG monotherapy were 39%, 31%, 22% and 15%, respectively. The pooled objective response rate of 131 I-MIBG in combination with other therapies was 28%. The pooled 1-year survival and 5-year survival rates were 64% and 32%. The pooled occurrence rates of thrombocytopenia and neutropenia in MIBG monotherapy studies were 53% and 58%. In the studies of 131 I-MIBG combined with other therapies, the pooled occurrence rates of thrombocytopenia and neutropenia were 79% and 78%. Conclusion 131 I-MIBG treatment alone or in combination of other therapies is effective on clinical outcomes in the treatment of neuroblastoma, individualized 131 I-MIBG is recommended on a clinical basis.